Aurobindo’s wholly owned subsidiary, Eugia Pharma Specialities, has received the Food and Drug Administration’s permission to ...

A quarter century of groundbreaking research has transformed the landscape for treating Philadelphia chromosome–positive leukemia.

Kidney fibrosis, a common endpoint of chronic kidney disease (CKD), is strongly linked to aging, with cellular senescence ...

Scientists identify three distinct types of 'senescent' skin cells, opening the door to more precise therapies.

Biocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore. The company's biosimilars achieved impressive global sales, and strategic ...

Imatinib (Gleevec®) was the first TKI approved in 2001, and it dramatically improved outcomes. Since then, second-generation TKIs like dasatinib, nilotinib, and bosutinib have joined the lineup. These ...

The performance was primarily driven by contributions from new product launches, notably Lenalidomide and Dasatinib in the US, supported by modest growth in the API business. “Looking ahead, we remain ...

Dasatinib (Sprycel) is another TKI that targets the BCR-ABL protein. This drug is a pill taken once a day with or without food. Dasatinib can be used as the first treatment for CML, but it can also be ...

Bengaluru-based biopharma major Biocon on Thursday reported a 153 per cent year-on-year (YoY) rise in consolidated net profit to ₹344 crore for the fourth quarter of FY25, compared to ₹ 136 crore in ...